A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT ID: NCT04175613
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
160 participants
INTERVENTIONAL
2019-12-20
2025-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will consist of up to 208 weeks of long-term treatment followed by an 8-week observational follow-up phase.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with Apremilast
Subjects with a weight between 20 kg to \< 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
Apremilast
Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apremilast
Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject is male or female 6 to 17 years of age, inclusive, at the time the informed consent document is signed by the legal guardian.
2. Subject must have a weight of ≥ 20 kg.
3. Subjects must have an age and sex specific BMI value no lower in range than the 5th percentile on the Centers for Disease Control (CDC) growth chart for children and adolescents.
4. Subject must have completed Week 52 (Apremilast Extension Phase) of Study CC-10004-PPSO-003.
5. Subject is able to sign an assent with a legal guardian/s who understand/s and voluntarily sign/s an informed consent prior to any study-related assessments/procedures being conducted.
6. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
7. All female subjects of childbearing potential (FCBP) must either practice abstinence from heterosexual contact or use one of the approved contraceptive options as described below while on apremilast and for at least 28 days after administration of the last dose of apremilast. For the purpose of this study, a female subject is considered of childbearing potential if she is ≥ 12 years old or has reached menarche, whichever occurred first.
At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the Investigator will educate the subject regarding abstinence or contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.
Females of childbearing potential must have a negative pregnancy test at each visit. All FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
Option 1: Any one of the following effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy;
OR
Option 2: Male or female condom or nonlatex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane\]; PLUS one additional barrier method:
(a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
NOTE: Option 2 may not be acceptable as a contraception option in all countries per local guidelines/regulations.
Exclusion Criteria
1. Subject has a condition, including the presence of laboratory abnormalities, or psychiatric illness, that would place the subject at unacceptable risk if he/she were to participate in the study.
2. Subject has a condition that confounds the ability to interpret data from the study.
3. Subject has evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments.
4. Subject is pregnant or breastfeeding.
5. Subject has guttate, erythrodermic, or pustular psoriasis.
6. Subject has active tuberculosis (TB) or a history of incompletely treated TB.
7. Subject answers "Yes" to any question on the Columbia-Suicide Severity Rating Scale at Visit 16 of study CC-10004-PPSO-003.
8. Subject plans concurrent use of the following therapies that may have a possible effect on psoriasis.
1. Conventional systemic therapy for psoriasis (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters)
2. Biologic therapy:
i. Etanercept (or biosimilar) treatment ii. Adalimumab (or biosimilar) treatment iii. Other TNF or interleukin (IL)-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) iv. Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) c) Use of any investigational drug other than apremilast
9. Subject has prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
10. Children in Care: a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Childrens Hospital
Phoenix, Arizona, United States
Johnson Dermatology Clinic
Fort Smith, Arkansas, United States
First OC Dermatology
Irvine, California, United States
Stanford University School of Medicine
Palo Alto, California, United States
California Dermatology Institute
Thousand Oaks, California, United States
Solutions Through Advanced Research Inc
Jacksonville, Florida, United States
Ciocca Dermatology
Miami, Florida, United States
Skin Care Physicians of Georgia
Macon, Georgia, United States
Dawes Fretzin Dermatology Group Inc
Indianapolis, Indiana, United States
Wright State Physicians
Fairborn, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Driscoll Childrens Hospital
San Antonio, Texas, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Centre Hospitalier Universitaire Saint Pierre
Brussels, , Belgium
Cliniques Universitaires Saint Luc
Brussels, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Stollery Childrens Hospital
Edmonton, Alberta, Canada
Winnipeg Clinic Dermatology Research
Winnipeg, Manitoba, Canada
Karma Clinical Trials
St. John's, Newfoundland and Labrador, Canada
AvantDerm
Toronto, Ontario, Canada
Fakultni nemocnice Kralovske Vinohrady
Prague, , Czechia
Synexus Czech sro
Prague, , Czechia
Cabinet du Docteur Ruer-Mulard Mireille
Martigues, , France
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
Toulouse, , France
Soroka University Medical Center
Bear Sheva, , Israel
Azienda Ospedaliero Universitaria Di Cagliari
Cagliari, , Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, , Italy
Azienda Ospedaliera di Padova
Padua, , Italy
Altai State Medical University
Barnaul, , Russia
Chelyabinsk Regional Clinical Skin and Venereal Dispensary
Chelyabinsk, , Russia
Republican Clinical Dermatology and Venerology Dispensary
Kazan', , Russia
Clinical Dispensary of Dermatology and Venereology of Krasnodar Territory of the Ministry of Health
Krasnodar, , Russia
State Scientific Center for Dermatovenereology and Cosmetology
Moscow, , Russia
Moscow Scientific Practical Center of Dermatology Venerology and Cosmetology
Moscow, , Russia
National Medical Research Center for Children Health
Moscow, , Russia
LLC Medical Center Zdorovaya Semiya
Novosibirsk, , Russia
Pierre Wolkenshtein Skin Diseases Clinic LLC
Saint Petersburg, , Russia
Saint Petersburg State Pediatric Medical University
Saint Petersburg, , Russia
LLC PiterKlinika
Saint Petersburg, , Russia
Bashkiria State Medical University
Ufa, , Russia
Yarosavl State Medical Academy
Yaroslavl, , Russia
Ural Scientific Research Institute of Dermatovenereology and Immunopathology
Yekaterinburg, , Russia
Hospital Sant Joan de Deu
Esplugues de Llobregat, Catalonia, Spain
General University Hospital of Alicante
Alicante, , Spain
Hopsital Germans Trias I Pujol
Badalona, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Hospital Infantil Universitario Nino Jesus
Madrid, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital Marques de Valdecilla
Santander, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1242-3537
Identifier Type: OTHER
Identifier Source: secondary_id
2019-003497-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-10004-PPSO-004
Identifier Type: -
Identifier Source: org_study_id